Apoptosis, proliferation, and Fas (APO-1, CD95)/Fas ligand expression in medullary carcinoma of the breast

Journal of Pathology

Volumn 192, Issue 2, 2000, Pages 166-173

  Yakirevich, Evgeny ^a,b   Maroun, Lisa ^a,b   Cohen, Oded ^a,b   Izhak, Ofer Ben ^b   Rennert, Gad ^a,b   Resnick, Murray B ^a,b  

^a CARMEL MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Apoptosis; Breast; Fas; FasL; Medullary carcinoma; PCNA; Proliferation; TUNEL

Indexed keywords

CD3 ANTIGEN; CD8 ANTIGEN; CYCLINE; FAS ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CELL PROLIFERATION; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MEDULLARY CARCINOMA; NICK END LABELING; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; TUMOR GROWTH;

EID: 0033775979     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/1096-9896(2000)9999:9999<::AID-PATH689>3.0.CO;2-A     Document Type: Article

References (37)

1. Medullary carcinoma of the breast. A clinicopathologic study with 10 year follow-up
2. Medullary carcinoma of the breast: A clinicopathologic study with appraisal of current diagnostic criteria
3. Prognostic comparison of three classifications for medullary carcinomas of the breast
4. MIB-1 expression in breast carcinomas with medullary features. An immunohistochemical study including correlation with p53 and bcl-2
5. Cytotoxic phenotype of tumor infiltrating lymphocytes in medullary carcinoma of the breast
6. Execution and suicide: Cytotoxic lymphocytes enforce Draconian laws through separate molecular mechanisms
7. Granzymes, a family of serine proteases released from granules of cytotoxic lymphocytes upon T cell receptor activation
8. The Fas death factor
9. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells
10. CD95 (APO-1/Fas)-associated signalling proteins
11. Apoptosis by death factor
12. Fas ligand-induced apoptosis as a mechanism of immune privilege
13. A role of CD95 ligand in preventing graft rejection
14. Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between mother and the conceptus
15. Fas ligand is not only expressed in immune privileged human organs but is also coexpressed with Fas in various epithelial tissues
16. Tumor expression of Fas ligand (CD95L) and the consequences
17. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand
18. The extent of apoptosis is inversely associated with bcl-2 expression in premalignant and malignant breast lesions
19. Spontaneous apoptosis is inversely related to intratumoral microvessel density in gastric carcinoma
20. Histopathological evaluation of apoptosis in cancer
21. Apoptosis in breast cancer as related to histopathological characteristics and prognosis
22. Apoptosis during breast carcinoma progression
23. Apoptosis and cell proliferation in medullary carcinoma of the breast: A comparative study between medullary and non-medullary carcinoma using the TUNEL method and immunohistochemistry
24. Fas expression and function in normal and malignant cell lines
25. CD95(APO-1/ Fas)-mediated apoptosis in normal and malignant liver, colon, and hematopoietic cells
26. Up-regulation of Fas (APO-1/CD95) ligand and down regulation of Fas expression in human esophageal cancer
27. Expression of Fas (CD95/APO-1) and Fas ligand in lung cancer, its prognostic and predictive relevance
28. Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer
29. The Fas/Fas-ligand system: A mechanism for immune evasion in human breast carcinomas
30. Expression of Fas (CD95/APO-1) ligand by human breast cancers: Significance for tumor immune privilege
31. CD95 ligand expression in dedifferentiated breast cancer
32. The Fas counterattack in vivo: Apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma
33. The Fas counterattack: A molecular mechanism of tumor immune privilege
34. Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanism for tumor killing
35. Antitumor effect of locally produced CD95 ligand
36. In vivo patterns of bcl-2 family protein expression in breast carcinomas in relation to apoptosis
37. Nuclear p53 protein accumulates preferentially in medullary and high-grade ductal but rarely in lobular breast carcinomas